Changes in @entity2956 XXXX and other symptoms across the menstrual cycle.

@entity1 @entity172 @entity2956 @entity1109 @entity158 @entity1118
The objective of this study was to assess changes in levels of clinical @entity2956 ( @entity2956 ) @entity158 in relation to phases of the menstrual cycle. @entity2956 cases were 35 @entity1 not using oral contraceptives (OCs); 35 @entity1 using OCs; and 21 @entity1 . Controls were 35 normally cycling @entity1 without @entity2956 or other @entity1118 . Subjects kept daily diaries over three menstrual cycles, reporting average and @entity158 , general and @entity1109 . Data were subject-centered and de-trended using the residuals from a random-effects linear regression model. To test for cyclic variation, cycles were standardized to 28 days and data were grouped into 9 periods/cycle (Days 1-3, 4-6, em leader, 22-24, 25-28). Overall levels of average @entity158 , @entity158 and symptoms did not differ across @entity2956 subject groups. For @entity158 , multivariate analysis of variance revealed a statistically significant difference across 3-day periods for normally cycling @entity1 with @entity2956 (P=0.011) and for @entity1 using OCs (P=0.017). In both groups, @entity158 levels rose toward the end of the cycle and peaked during menstruation. In @entity1 not using OCs, there was a secondary @entity158 peak at Days 13-15, around the time of ovulation. This peak was not seen in @entity1 using OCs. There was no statistically significant difference over time periods for @entity1 (P=0.94). Similar patterns were found for average @entity158 , as well as PMS symptoms and general somatic symptoms. These results suggest that @entity158 in @entity1 is highest at times of lowest @entity172 , but rapid @entity172 change may also be associated with @entity158 .
